Respiratory Syncytial Virus Infection in High-risk Infants - an Update on Palivizumab Prophylaxis - Wikidata - awgldk - TriplyDB

Respiratory Syncytial Virus Infection in High-risk Infants - an Update on Palivizumab Prophylaxis

Respiratory Syncytial Virus Infection in High-risk Infants - an Update on Palivizumab Prophylaxis

http://www.wikidata.org/entity/Q34049590

about

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children.Risk of Readmission for Wheezing during Infancy in Children with Congenital Diaphragmatic Hernia.Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention.Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.Burden of Respiratory Syncytial Virus Hospitalizations in Canada.Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England.

P2860

Q28072535-80A3298D-E5F5-4161-B939-586B0FDA10CA Q35157930-9E6D6191-049C-4CA8-9D63-FCD860ED1F3D Q36015409-A1EC514B-9C6D-4A58-A1B0-0CE73ED71BD3 Q37729137-3C690E6E-F200-49CC-B819-7337E8F7AD8A Q38604949-74111A85-3DE4-4B8D-B562-F4FA1530A1C2 Q38671952-FC0A2C4F-C51A-495F-AAFF-F890243F4529 Q47194968-3EE87C31-62BB-4589-A25E-14D2B3F72D8F Q53693691-66FA7767-0C9B-41D1-B910-039DD0CFD73A

P2860

Respiratory Syncytial Virus Infection in High-risk Infants - an Update on Palivizumab Prophylaxis

http://www.wikidata.org/entity/Q34049590

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Respiratory Syncytial Virus In ...... ate on Palivizumab Prophylaxis

@ast

Respiratory Syncytial Virus In ...... ate on Palivizumab Prophylaxis

@en

Respiratory Syncytial Virus In ...... ate on Palivizumab Prophylaxis

@nl

type

label

Respiratory Syncytial Virus In ...... ate on Palivizumab Prophylaxis

@ast

Respiratory Syncytial Virus In ...... ate on Palivizumab Prophylaxis

@en

Respiratory Syncytial Virus In ...... ate on Palivizumab Prophylaxis

@nl

prefLabel

Respiratory Syncytial Virus In ...... ate on Palivizumab Prophylaxis

@ast

Respiratory Syncytial Virus In ...... ate on Palivizumab Prophylaxis

@en

Respiratory Syncytial Virus In ...... ate on Palivizumab Prophylaxis

@nl

P1433

Q34049590-923C7205-4AFA-45E3-8375-A5C84BF7D5AA

P1476

Q34049590-0400D3E1-7E0D-41CC-9930-7C5D4AD5B7B5

P2093

Q34049590-F9ADF9C8-CBFF-4663-8836-6315CF1717A9

P2860

Q34049590-02AEC1E3-AB7A-4A17-A656-2D9DEFC33C40

Q34049590-1794A708-E625-45CD-8A80-EB9C1389E019

Q34049590-18F04ECF-DA92-4449-9B82-C5736367F59C

Q34049590-1AE5642C-F79E-41A1-8989-BBEA923DA16A

Q34049590-1CE6EA25-7651-44F7-8769-8631F669F0B2

Q34049590-2DF33938-466E-40F0-A638-55135E46E3C4

Q34049590-33FD7486-BA5B-4514-8E9E-F29C9C115641

Q34049590-4EB3FD5E-03BB-49F7-BD22-B2B197C1493D

Q34049590-555CB39B-7811-45C6-90F0-870B6A044A12

Q34049590-56D70AD4-1036-4A1E-B1BE-60424C43D4E3

P304

Q34049590-DA994769-D2CA-4715-A19D-85E31AD16671

P31

Q34049590-D149F5F9-04BD-415A-8E27-4B8F11070667

P356

Q34049590-1B4B17B9-A840-495B-85A3-7B5BABEBE8CB

P478

Q34049590-E911465F-1E22-4050-A9F3-1F032CD271D1

P577

Q34049590-2C7DBC85-0AB4-41BF-81EE-4BADFD47FBC7

P5875

Q34049590-C4684FDC-AE2A-451C-BF35-C6C55A21A745

P698

Q34049590-CE4A81F8-4CD2-478F-9514-DE940B5E4F45

P932

Q34049590-18DC91D0-2F6E-4A05-A1C5-3173B060DFB7

P356

1874285801408010071

P1433

The Open Microbiology Journal

P1476

Respiratory Syncytial Virus In ...... ate on Palivizumab Prophylaxis

@en

P2093

Bernhard Resch

http://www.w3.org/2001/XMLSchema#string

P2860

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis

Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study.

Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.

Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.

Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children.

Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study.

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).

P304

71-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/1874285801408010071

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264832226

http://www.w3.org/2001/XMLSchema#string

P698

25132870

http://www.w3.org/2001/XMLSchema#string

P932

4133922

http://www.w3.org/2001/XMLSchema#string